...
首页> 外文期刊>Stem cells and development >Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells.
【24h】

Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells.

机译:用 FLT3L、干细胞因子、白细胞介素-6 和 IL-3 培养的脐带血 CD34+ 细胞产生 CD11c+CD1a-/c- 髓样树突状细胞。

获取原文
获取原文并翻译 | 示例

摘要

Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34(+) cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c(+)CD16() CD1a()/c() MDCs from CB CD34(+) cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33(+)CD14()CD15() precursors with a mean of 4 x 10(6) cells generated from 1-4 x 10(4) CB CD34(+) cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34(+) cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.
机译:允许从 CD34(+) 细胞扩增髓系树突状细胞 (MDC) 的方法对于增强脐带血 (CB) 造血干细胞移植 (HSCT) 后的抗白血病反应具有潜在重要意义。我们发现早期作用细胞因子 FLT3 配体 (FL)、干细胞因子 (SCF)、白细胞介素 (IL)-3 和 IL-6 的组合支持从 CB CD34(+) 细胞或 CB 髓系前体生成 CD11c(+)CD16()CD1a()/c() MDC。早期作用的细胞因子衍生的MDC维持在髓系CD33(+)CD14()CD15()前体内,平均2周后由1-4×10(4)CB CD34(+)细胞或髓系前体产生4 x 10(6)个细胞。培养 8-12 天后,与成人血液 MDC 相比,MDC 表达更高水平的 HLA-DR 抗原,但 CD40 和 CD86 抗原水平较低。在这个分化阶段,早期作用的细胞因子衍生的MDCs已经获得了诱导更大的同种异体T细胞增殖的能力,而不是来自同一培养物的单核细胞或粒细胞。暴露于包括 IL-1β、IL-6、肿瘤坏死因子 (TNF)-α 和前列腺素 E (PGE)-2 的细胞因子混合物 (CC) 的早期作用细胞因子衍生的 MDC,上调了表面共刺激分子 CD40 和 CD86 并增强了同种异体 T 细胞增殖,这是 MDC 成熟的特征。从 CB CD34(+) 细胞可靠地生产 MDC,为研究其谱系承诺途径提供了一种新方法,也是一种用 MDC 富集 CB 的潜在方法,以改善 CB HSCT 后 DC 免疫治疗的前景。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号